Zhejiang Jolly Pharmaceutical Co Ltd
SZSE:300181

Watchlist Manager
Zhejiang Jolly Pharmaceutical Co Ltd Logo
Zhejiang Jolly Pharmaceutical Co Ltd
SZSE:300181
Watchlist
Price: 16.3 CNY -1.87% Market Closed
Market Cap: 11.4B CNY
Have any thoughts about
Zhejiang Jolly Pharmaceutical Co Ltd?
Write Note

Profitability Summary

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
Zhejiang Jolly Pharmaceutical Co Ltd

Revenue
2.4B CNY
Cost of Revenue
-865.8m CNY
Gross Profit
1.5B CNY
Operating Expenses
-932.6m CNY
Operating Income
560.8m CNY
Other Expenses
-79.5m CNY
Net Income
481.3m CNY

Margins Comparison
Zhejiang Jolly Pharmaceutical Co Ltd Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
CN
Zhejiang Jolly Pharmaceutical Co Ltd
SZSE:300181
11.4B CNY
63%
24%
20%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-3%
-83%
-79%
US
Eli Lilly and Co
NYSE:LLY
793.7B USD
81%
35%
19%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
3%
-4%
DK
Novo Nordisk A/S
CSE:NOVO B
3.4T DKK
85%
45%
35%
US
Johnson & Johnson
NYSE:JNJ
385.5B USD
69%
28%
17%
US
Merck & Co Inc
NYSE:MRK
260.6B USD
76%
29%
22%
CH
Roche Holding AG
SIX:ROG
213.6B CHF
73%
32%
20%
UK
AstraZeneca PLC
LSE:AZN
171.2B GBP
82%
21%
13%
CH
Novartis AG
SIX:NOVN
183.5B CHF
75%
29%
33%
US
Pfizer Inc
NYSE:PFE
161.4B USD
71%
22%
7%
Country CN
Market Cap 11.4B CNY
Gross Margin
63%
Operating Margin
24%
Net Margin
20%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Operating Margin
-83%
Net Margin
-79%
Country US
Market Cap 793.7B USD
Gross Margin
81%
Operating Margin
35%
Net Margin
19%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Operating Margin
3%
Net Margin
-4%
Country DK
Market Cap 3.4T DKK
Gross Margin
85%
Operating Margin
45%
Net Margin
35%
Country US
Market Cap 385.5B USD
Gross Margin
69%
Operating Margin
28%
Net Margin
17%
Country US
Market Cap 260.6B USD
Gross Margin
76%
Operating Margin
29%
Net Margin
22%
Country CH
Market Cap 213.6B CHF
Gross Margin
73%
Operating Margin
32%
Net Margin
20%
Country UK
Market Cap 171.2B GBP
Gross Margin
82%
Operating Margin
21%
Net Margin
13%
Country CH
Market Cap 183.5B CHF
Gross Margin
75%
Operating Margin
29%
Net Margin
33%
Country US
Market Cap 161.4B USD
Gross Margin
71%
Operating Margin
22%
Net Margin
7%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
Zhejiang Jolly Pharmaceutical Co Ltd Competitors

Country Company Market Cap ROE ROA ROCE ROIC
CN
Zhejiang Jolly Pharmaceutical Co Ltd
SZSE:300181
11.4B CNY
18%
13%
20%
22%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-441%
-47%
-108%
-64%
US
Eli Lilly and Co
NYSE:LLY
793.7B USD
60%
12%
33%
19%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
-2%
2%
2%
DK
Novo Nordisk A/S
CSE:NOVO B
3.4T DKK
89%
28%
77%
37%
US
Johnson & Johnson
NYSE:JNJ
385.5B USD
20%
8%
18%
13%
US
Merck & Co Inc
NYSE:MRK
260.6B USD
33%
13%
21%
17%
CH
Roche Holding AG
SIX:ROG
213.6B CHF
40%
13%
29%
22%
UK
AstraZeneca PLC
LSE:AZN
171.2B GBP
17%
6%
14%
12%
CH
Novartis AG
SIX:NOVN
183.5B CHF
35%
16%
20%
15%
US
Pfizer Inc
NYSE:PFE
161.4B USD
5%
2%
7%
8%
Country CN
Market Cap 11.4B CNY
ROE
18%
ROA
13%
ROCE
20%
ROIC
22%
Country JP
Market Cap 776 550.9T JPY
ROE
-441%
ROA
-47%
ROCE
-108%
ROIC
-64%
Country US
Market Cap 793.7B USD
ROE
60%
ROA
12%
ROCE
33%
ROIC
19%
Country UK
Market Cap 440.4B GBP
ROE
-4%
ROA
-2%
ROCE
2%
ROIC
2%
Country DK
Market Cap 3.4T DKK
ROE
89%
ROA
28%
ROCE
77%
ROIC
37%
Country US
Market Cap 385.5B USD
ROE
20%
ROA
8%
ROCE
18%
ROIC
13%
Country US
Market Cap 260.6B USD
ROE
33%
ROA
13%
ROCE
21%
ROIC
17%
Country CH
Market Cap 213.6B CHF
ROE
40%
ROA
13%
ROCE
29%
ROIC
22%
Country UK
Market Cap 171.2B GBP
ROE
17%
ROA
6%
ROCE
14%
ROIC
12%
Country CH
Market Cap 183.5B CHF
ROE
35%
ROA
16%
ROCE
20%
ROIC
15%
Country US
Market Cap 161.4B USD
ROE
5%
ROA
2%
ROCE
7%
ROIC
8%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More
Back to Top